Revisão sistemática | Agonistas receptores de GLP-1 e inibidores de SGLT-2 parecem reduzir o risco de morte por doença cardiovascular e morte por qualquer causa em pessoas com diabetes e doença cardiovascular estabelecida.

Dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide 1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors for people with cardiovascular disease: a network meta‐analysis – Cochrane Library

Resumo: The effects of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors for people with cardiovascular disease – Cochrane Library

Comentário no Twitter

The effects of DPP‐4 inhibitors, GLP‐1 receptor agonists and SGLT‐2 inhibitors for people with #CardiovascularDisease https://t.co/0FwffSCqbC New @CochraneHeart network meta-analysis looks at evidence from 31 studies. #CardiovascularResearch

— The Cochrane Library (@CochraneLibrary) October 27, 2021